Tzield savings card: as little as $0 a treatment with commercial insurance

Tzield is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Tzield is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameTzield

Authorized genericteplizumab-mzwv

Regular genericteplizumab-mzwv

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Tzield?

The original

–

Brand nameThe maker’s card

TZIELD Copay Program

Savings card from Sanofi

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a treatment

The card takes up to $22,000 a year off your co-pay.

Or call 1-844-778-2246.

In the maker’s words

“With the TZIELD Copay Program, eligible, commercially insured patients may pay as little as $0 for treatment.”

From the maker’s offer on tzield.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Tzield itself, from the same company, sold without the brand name, and usually for less. For now Tzield is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Tzield is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TZIELD is a CD3-directed antibody indicated to:

Delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D.
Delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. This indication is approved under accelerated approval based on evidence of reduced C-peptide decline. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Limitations of Use:

There is limited evidence of safety and effectiveness in patients aged 45 years and older with Stage 2 T1D.
TZIELD is not effective as a disease modifying therapy in non-autoimmune dysglycemic conditions.

Source: the FDA label for Tzield (Provention Bio, Inc.), August 14, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tzield/